To critically evaluate the limitations of B-cell depletion therapies in rheumatoid arthritis (RA) and explore novel therapeutic strategies, emphasizing the need for a paradigm shift.
Key Findings:
Approximately 40% of RA patients show non-response to rituximab, highlighting limitations in B-cell depletion strategies and the need for alternative approaches.
Protective anti-citrullinated protein antibody (ACPA) clones and regulatory B cells (Bregs) play crucial roles in modulating inflammation, suggesting a dual role for B cells.
Rituximab resistance is linked to the survival of CD20-negative plasmablasts and the persistence of mutated B-cell receptor clonotypes, indicating complex mechanisms of evasion.
CD19 CAR T-cell therapy demonstrates potential for achieving drug-free remission in multidrug-refractory RA, representing a significant advancement in treatment options.
Interpretation:
The findings suggest a need to shift from traditional B-cell depletion approaches to strategies that consider the dual role of B cells in RA, emphasizing the importance of immune restoration and the potential of novel therapies.
Limitations:
The review is based on available literature, which may not encompass all recent developments, and potential biases in study selection should be acknowledged.
Clinical data on CAR T-cell therapy in RA is still emerging and requires further validation to establish its efficacy and safety.
Conclusion:
A comprehensive understanding of B-cell biology in RA can lead to improved therapeutic strategies, including the promising role of CAR T-cell therapy in achieving deeper immune restoration and better patient outcomes.
